NASDAQ:AYLAKeros Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Keros Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.01 -0.05 (-0.33 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$15.00Now: $15.01▼$15.2750-Day Range N/A52-Week Range$14.63Now: $15.01▼$16.50Volume12,000 shsAverage Volume85,164 shsMarket Capitalization$186.81 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsHeadlinesSocial Media Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Keros Therapeutics. Previous Next 0.0 Community Rank Outperform VotesKeros Therapeutics has received 0 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKeros Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)MarketBeat's community ratings are surveys of what our community members think about Keros Therapeutics and other stocks. Vote “Outperform” if you believe AYLA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AYLA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKeros Therapeutics does not currently pay a dividend.Dividend GrowthKeros Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Keros Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.00 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AYLA Previous Symbol CUSIPN/A CIKN/A Webwww.ayalapharma.com Phone972-8373-1541Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees29 Outstanding Shares12,446,000Market Cap$186.81 million Next Earnings DateN/A OptionableNot Optionable NASDAQ:AYLA Rates by TradingView Receive AYLA News and Ratings via Email Sign-up to receive the latest news and ratings for AYLA and its competitors with MarketBeat's FREE daily newsletter. Keros Therapeutics (NASDAQ:AYLA) Frequently Asked Questions Has Keros Therapeutics been receiving favorable news coverage? Media headlines about AYLA stock have trended negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Keros Therapeutics earned a daily sentiment score of -2.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutKeros Therapeutics. Who are some of Keros Therapeutics' key competitors? Some companies that are related to Keros Therapeutics include Nextgen Healthcare (NXGN), Collegium Pharmaceutical (COLL), Surgery Partners (SGRY), Eagle Pharmaceuticals (EGRX), Molecular Templates (MTEM), PureTech Health (PRTC), Arcturus Therapeutics (ARCT), Codexis (CDXS), Sienna Senior Living (SIA), Akero Therapeutics (AKRO), Kadmon (KDMN), Mayne Pharma Group (MYX), Replimune Group (REPL), Retrophin (RTRX) and Morphic (MORF). View all competitors. What other stocks do shareholders of Keros Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include Okta (OKTA), Merck & Co., Inc. (MRK), LogicBio Therapeutics (LOGC), Corning (GLW), Greenbrier Companies (GBX), Fortinet (FTNT), Equinix (EQIX), Eloxx Pharmaceuticals (ELOX), Docusign (DOCU) and Citrix Systems (CTXS). Who are Keros Therapeutics' key executives? Keros Therapeutics' management team includes the following people: Dr. Roni Mamluk, CEO & Director (Age 53)Mr. Yossi Maimon CPA, CPA, MBA, Chief Financial Officer (Age 49)Dr. Gary B. Gordon M.D., Ph.D., Chief Medical Officer (Age 67) When did Keros Therapeutics IPO? (AYLA) raised $50 million in an initial public offering (IPO) on Friday, May 8th 2020. The company issued 3,300,000 shares at $14.00-$16.50 per share. Citigroup and Jefferies served as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers. What is Keros Therapeutics' stock symbol? Keros Therapeutics trades on the NASDAQ under the ticker symbol "AYLA." When does the company's quiet period expire? Keros Therapeutics' quiet period expires on Wednesday, June 17th. Keros Therapeutics had issued 3,666,667 shares in its IPO on May 8th. The total size of the offering was $55,000,005 based on an initial share price of $15.00. During the company's quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. How do I buy shares of Keros Therapeutics? Shares of AYLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Keros Therapeutics' stock price today? One share of AYLA stock can currently be purchased for approximately $15.01. How big of a company is Keros Therapeutics? Keros Therapeutics has a market capitalization of $186.81 million. Keros Therapeutics employs 29 workers across the globe. What is Keros Therapeutics' official website? The official website for Keros Therapeutics is www.ayalapharma.com. How can I contact Keros Therapeutics? Keros Therapeutics' mailing address is Oppenheimer 4, Rehovot L3, 7670104. The company can be reached via phone at 972-8373-1541 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
